Guidelines for the treatment of chronic heart failure (CHF), for example, have been widely advocated to promote better outcomes. 1, [11] [12] [13] An extensive body of literature has demonstrated that several pharmacologic therapies such as angiotensin-converting enzyme (ACE) inhibitors, [14] [15] [16] β-blockers, 17, 18 and spironolactone 19 can significantly decrease mortality and may improve symptoms of CHF. Although guidelines for management of CHF exist, case finding is difficult. Signs and symptoms of CHF (eg, dyspnea, fatigue, and edema) are nonspecific and may be subtle in many patients. 13 Imaging studies, although sensitive and specific, are not always obtained to investigate these symptoms. Patients with controlled CHF are often treated on an outpatient basis, making hospital discharge diagnoses an insensitive indicator. In addition, discharge diagnoses may be inaccurate because of inadvertent or intentional coding errors. On the other hand, outpatient diagnoses are often incomplete. Moreover, current treatment guidelines for CHF do not apply to all patients with CHF. Rather, they apply only to those with left ventricular systolic dysfunction (LVSD). 13 Medical management for left ventricular diastolic dysfunction is considerably different. As many as 40% of patients with heart failure have preserved systolic function, excluding them from published guidelines developed for patients with left ventricular dysfunction. 13, 20 Because current International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 21 codes for heart failure do not distinguish between left ventricular diastolic dysfunction and LVSD, use of discharge diagnoses alone will identify many patients for whom current guidelines are not relevant. Currently, only a cardiac imaging test such as echocardiography or radionuclide studies can accurately differentiate between these 2 groups of patients.
In this study we sought to compare different methods for using commonly available computerized data to identify patients with LVSD who would be candidates for treatment according to currently accepted treatment guidelines.
Methods

Study setting
This study was performed in the General Internal Medicine Clinic (GIMC) at the Department of Veterans Affairs (VA) Puget Sound Health Care System, a large, tertiary universityaffiliated referral center located in Seattle, Wash.
Subjects and design
We performed a cross-sectional study that included patients who were seen in the GIMC and who had echocardiography or radionuclide ventriculography (RNVG) performed as part of regular clinical care between January 1, 1996, and January 21, 2000.
Patients were considered to have LVSD if they met at least one of the following criteria: (1) a clinical interpretation of LVSD on the echocardiography or RNVG report, (2) an ejection fraction <40%, (3) an interpretation of enlarged left ventricle, (4) global wall motion abnormality, (5) fractional shortening of <25%, or (6) left ventricular end-diastolic diameter ≥6 cm.
Data sources and variable definitions
We extracted information from the Consumer Health Information and Performance Sets (CHIPS), a data warehouse that contains comprehensive electronic medical information from the 7 VA medical centers and 1 domiciliary unit that comprise the Northwest Veterans Integrated Service Network (number 20). Data residing in CHIPS include demographic information, diagnoses, and electronic progress notes from outpatient visits and hospitalizations, outpatient and inpatient pharmacy records, and results of laboratory and radiologic studies.
We obtained data that were available from CHIPS between January 1, 1996, and January 21, 2000. This information included all demographic information, inpatient and outpatient diagnoses (coded in ICD-9-CM), and comprehensive outpatient pharmacy records from the CHIPS data warehouse. For the purposes of this study, we did not restrict the timing of the assessment of pharmacy data or of clinical diagnosis on the basis of the echocardiography date. We used ICD-9-CM codes 428.x (heart failure) and 398.91 (rheumatic heart failure) to define a diagnosis of CHF. Patients were considered to have filled a prescription if they picked up or were mailed the medication. For this study, both inpatient and outpatient diagnoses and pharmacy data were recorded as dichotomous variables regardless of repetitiveness of diagnoses or length of exposure to a medication. Race was stratified into 3 categories (white, African American, other).
Statistical analysis and model development
Intergroup differences for individual variables were evaluated with the t test for continuous variables (eg, age), and the χ 2 test for categorical variables.
We classified patients according to the presence or absence of LVSD and created a series of discriminant models with use of demographic and clinical variables that would be available in many clinical settings. The discriminant models were generated by a forward-stepwise method after demonstration that models developed with different statistical techniques (multivariate logistic regression, forward and backward, or stepwise discriminant analysis) produced similar results on a subset of our patient population. The discriminant function produces the best discrimination between the groups with and without LVSD on the basis of the linear combinations of predictor variables. Most textbooks derive the linear discriminant function assuming multivariate normal independent variables. However, Fisher (1936) did not use a normal distribution assumption, and it has been found that the linear discriminant function often performs well for binary independent variables. 22 By use of this technique, we created 4 discriminant models: (1) a model in which the independent variables were limited to diagnosis (including CHF) from inpatient and outpatient electronic medical records, (2) a model containing only information about medication, including combinations of medications such as the combination of an ACE inhibitor, a loop diuretic, and digoxin, (3) a model that combined both CHF diagnosis and medication, and (4) a model with CHF diagno-sis, associated diagnoses, and medication. We also examined the potential of effect-modifying variables such as the combination of a diagnosis of atrial fibrillation and digoxin.
To ensure a parsimonious model, the study sample was randomly split into halves to create a derivation set and a validation set. For each model developed, we compared the proportion of subjects correctly classified in the validation sets. We also calculated the sensitivity and specificity of the final models with use of the echocardiography or RNVG report as the reference standard. Two primary comparisons were then made: (1) the accuracy of the discriminant models to the echocardiography or RNVG report and (2) a comparison of the models to the electronic medical record diagnosis (ICD-9-CM) of CHF in correctly identifying patients.
In addition, we generated receiver-operating characteristic (ROC) curves to evaluate the discriminative ability between our predictive models and the diagnosis of CHF. The C-statistic (area under the ROC curve) was used to compare the performance of the different models.
Results
We identified 2246 patients who had at least one echocardiography or RNVG report. Of these patients, 778 (34.6%) had an echocardiogram or RNVG consistent with LVSD. Patients with LVSD tended to be slightly older than those without LVSD but were similar in terms of sex, race, and marital status (Table I) . Compared with patients without LVSD, those with LVSD were more likely to receive prescriptions for cardiovascular medications including ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril, trandolapril), loop diuretics (bumetanide, ethacrynic acid, furosemide, and torsemide), digoxin, carvedilol, nitrates (nitroglycerin and isosorbide dinitrate), hydralazine, and angiotensin II receptor antagonists (candesartan, losartan, and valsartan) (Table II) . In addition, aspirin use was also statistically higher for subjects Table II . Medications prescribed according to presence or absence of LVSD with LVSD. There were no statistically significant prescribing differences with regard to use of β-blockers (atenolol, labetalol, metoprolol, nadolol, pindolol, propranolol, and sotalol), with the exception of carvedilol, calcium channel blockers (amlodipine, diltiazem, felodipine, isradipine, nifedipine, verapamil), or nonloop diuretics (chlorthalidone, hydrochlorothiazide, indapamide, and metolazone). Prescriptions for nonsteroidal anti-inflammatory drugs were also not statistically different for the 2 groups. Many inpatient and outpatient ICD-9-CM coded diagnoses for related cardiovascular diseases were found in higher proportions for those with LVSD than those without (Table III) . Among patients with LVSD on the basis of an echocardiography report, the electronic medical records were also more likely to have diagnoses for abdominal aortic aneurysm, acute myocardial infarction, atherosclerosis, atrial fibrillation, chronic heart disease (defined as an ICD-9-CM of 429.x), CHF, chronic obstructive pulmonary disease, diabetes, hypertension, previous myocardial infarction, and unstable angina. A diagnosis of stroke was comparable between the 2 groups, and alcohol abuse, defined as an ICD-9-CM coding of either alcohol dependence syndrome or alcoholic cardiomyopathy, was negatively associated with LVSD.
The derivation and validation sets were similar with respect to demographic characteristics, ICD-9-CM diagnoses, and medication use. Table IV displays the standardized coefficients for each of the 4 discriminant models in the validation cohort. In models that contained ICD-9-CM information, comorbid conditions were highly associated with having LVSD. These included history of atrial fibrillation, acute myocardial infarction, previous myocardial infarction, and CHF. Models that contained medication and medication combinations such as ACE inhibitors and the combination of ACE inhibitor, loop diuretic, and digoxin also demonstrated strong associations and good predictive ability.
When we compared how accurately the different discriminant models predicted the presence of LVSD versus the presence of an ICD-9-CM diagnosis of CHF in the electronic medical record, the models incorporating pharmacy data, regardless of whether they contained an ICD-9-CM diagnosis of CHF, performed better than a model derived solely from all diagnoses or from an ICD-9-CM diagnosis of CHF alone (Table V) . Moreover, adding diagnostic information to pharmacy data only marginally improved the percent correct, positive predictive value, sensitivity, and discrimination of the model (C-statistic) ( Table V) .
A primary or secondary ICD-9-CM diagnosis of CHF from computerized medical records correctly classified patients with LVSD 72% of the time, whereas the discriminant model that included only pharmacy data was able to correctly classify subjects 75% of the time. On the basis of ROC analysis, the performance of the model incorporating pharmacy data was modestly superior (C-statistic 0.778) to that using an ICD-9-CM diagnosis of CHF alone (C-statistic 0.739). An ICD-9-CM diagnosis of CHF was more sensitive but less specific than the pharmacy-based discriminant function with a sensitivity of 80.2% versus 64.9%, and specificity of 67.6% versus 80.8%, respectively.
Discussion
Our study found that routinely collected data from outpatient pharmacy records were more accurate in identifying patients with LVSD than an ICD-9-CM diagnosis of CHF from electronic medical records. Adding ICD-9-CM diagnosis of CHF to the pharmacy-based models added only marginal improvements. These results suggest that pharmacy data can be used to facilitate Although heart failure is the most common diagnosis in hospital patients aged ≥65 years old, 23 clinical recognition and treatment of heart failure remains a difficult problem. Suboptimal patient care can occur when CHF is unrecognized or misclassified. Whether the failure to recognize CHF occurs as a result of errors in the clinical information system or clinician judgment, there may be important implications for patient care.
The model that we developed on the basis of pharmacy information demonstrated only modest improvement when primary and secondary diagnoses were entered. Although the sensitivity of an ICD-9-CM diagnosis of CHF was relatively high compared with the discriminant models, it resulted in a low specificity. There are a number of possible explanations for a false-positive or false-negative diagnosis of CHF when echocardiography or RNVG results are used as the criterion for LVSD. False positives could result from errors in clinical judgment 24 or record keeping or if the diagnosis was assigned during a transient episode of CHF. Recent descriptions of possible etiologies of heart failure resulting from diastolic dysfunction or transient systolic dysfunction may also explain a clinical diagnosis of CHF without echocardiographic evidence of LVSD. 25 False-negative diagnoses might also be due to inaccurate data entry, data system errors, or flawed clinical judgment. Another explanation might be that cardiac imaging results were obtained after initiation of therapy that normalized ventricular function, although this would likely occur only if the untreated impairment were mild. In addition, patients who had myocardial infarctions may have LVSD as a result of stunning but be given a clinical diagnosis of CHF in this setting. We American Heart Journal Volume 142, Number 6 Udris et al 1007 Table V . Discriminant models versus ICD-9-CM in identifying subjects with LVSD by echocardiography (validation sample used)
found, however, that 8 of the 2246 patients who did not have a diagnosis of CHF did have LVSD by echocardiography within 2 weeks of an admission for myocardial infarction. In our sample, approximately 20% of patients who had LVSD substantiated by cardiac imaging had not been assigned an ICD-9-CM diagnosis of heart failure. Another undetected source of potential false negatives was patients with LVSD who had neither a diagnosis of CHF from electronic records nor a recent cardiac imaging study. Some such patients may have been clinically recognized, for example, patients with long-term, stable CHF that had not required recent imaging and whose provider had recorded the diagnosis only in the paper record. There might also be other patients with CHF that has been unrecognized or misdiagnosed. Thus the estimates for falsenegative diagnosis in this study represent a minimum and might be substantially higher. There were several strengths to this study. First, we used a split-halves approach to model construction to avoid overfitting. 26, 27 Second, we used results of existing echocardiography and RNVG studies to document the presence of LVSD. Third, we had access to essentially complete outpatient pharmacy records. The VA dispenses medications at substantially reduced costs to patients, and previous studies have demonstrated that 98% to 99% of patients who receive care from the VA system fill all their medications at VA pharmacies. 28, 29 There were also limitations to our study. Because we studied only patients who had undergone echocardiography and RNVG, our results are limited to that population. However, cardiac imaging is recommended as the first diagnostic step in assessing patients suspected of having CHF. Because cardiac imaging is a diagnostic test typically used for patients with cardiac-related symptoms, it is likely that patients with more symptomatic disease were sampled. In addition, we were unable to assess whether subjects had cardiac imaging performed outside the VA medical system. Many patients, however, obtain diagnostic examinations through the VA because they are provided free of charge or at substantially reduced rates. The population for this study was composed largely of men, and the results of this study should not be extrapolated to populations outside the scope of this study.
Although there has been a phenomenal proliferation of computerized medical records, these systems may not contain the clinical information necessary to readily implement clinical reminder systems for managing chronic illness. For example, many systems lack complete or accurate information about diagnoses, severity of illnesses, or previous responses to therapy. Over time, it is likely that the clinical content of these systems will improve, but in the interim other strategies must be developed. One of these is the use of prediction models such as the one we have developed with pharmacy data.
Statistical models to identify patients must be carefully evaluated in every setting in which they are applied and must be updated frequently as standards of practice evolve. For example, during most of the period of the current study carvedilol, a β-blocker approved only for treatment of heart failure, was not widely available to clinicians in our system. Use of this drug was a highly specific (99.5%) but insensitive (5.8%) indicator for LVSD. However, more recently, there has been wider use of other β-blockers such as metoprolol for patients with CHF. Because metoprolol, unlike carvedilol, is used for a variety of other indications (eg, diastolic dysfunction, hypertension, angina, migraine headaches, and essential tremor), it would likely be a nonspecific indicator of LVSD. On the other hand, spironolactone has been recently demonstrated to improve survival among patients with LVSD and might become a more specific indicator.
In summary, we have demonstrated that an automated, computer-driven algorithm identifying LVSD permits simple, rapid, and timely identification of patients with CHF with use of only routinely collected administrative data. Future research is needed to develop accurate electronic identification of heart failure and other common chronic conditions. 30, 31 
